Moderna (MRNA) stock jumped more than 6% on Wednesday after the US Food and Drug Administration agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject ...
Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu ...
That raises the stakes for a second area of Moderna’s research. In a partnership with Merck, it’s been using its mRNA ...
Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday. Last week, the FDA sent a missive to Moderna ...
Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration will review Moderna's mRNA 1010 flu vaccine for older adults, which could make it available ...
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...
During the COVID-19 pandemic, President Donald Trump then described mRNA technology as a "modern-day miracle." HealthDay News — In a major blow to vaccine development, the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results